Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 4Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Technetium Tc 99m Sestamibi × Clear all
NCT02744053 2026-04-21

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
96 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02324387 2026-03-09

Tc99m Sestamibi Molecular Breast Imaging

M.D. Anderson Cancer Center

Phase NA Active not recruiting
96 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡